SeaStar Medical's QUELIMMUNE linked to higher 90-day survival in pediatric sepsis-associated kidney injury study
ICU•SeaStar Medical reported that an exploratory observational study linked QUELIMMUNE to significantly higher 90-day survival among critically ill children with sepsis-associated acute kidney injury versus a historical comparator. No device-related adverse events occurred among treated registry patients.
1. Study findings
Findings presented at ASN Kidney Week 2026 showed improved survival in the primary analysis compared with a historical comparator. The exploratory observational study supports an association with improved outcomes, not a causal treatment benefit; no device-related adverse events occurred among treated registry patients.
